Source: International Congress 2014 – Multidrug-resistant (MDR) pathogens that cause pneumonia
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Torres (Barcelona, Spain). PES (Pseudomonas , Enterobacteriaceae S. Aureus MR) a new clinical acronym to identify MDR pneumonias in the community. International Congress 2014 – Multidrug-resistant (MDR) pathogens that cause pneumonia

Member's Comments

No comment yet.

Related content which might interest you: Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors Source: Eur Respir J 2010; 35: 598-615 Year: 2010 Enterobacteriaceae and Pseudomonas aeruginosa in community-acquired pneumonia: the reality after a decade of uncertainty? Source: Eur Respir J 2010; 35: 473-474 Year: 2010 What is MRSA? Source: Eur Respir J 2009; 34: 1190-1196 Year: 2009 Predictive factors for methicillin-resistant Staphylococcus aureus (MRSA) infection in a MRSA screening protocol. Source: International Congress 2018 – Difficult-to-treat respiratory infections Year: 2018 Clinical outcomes of patients with hospital-acquired pneumonia due to community-associated methicillin resistant staphylococcus aureus (CA-MRSA) Source: Eur Respir J 2007; 30: Suppl. 51, 407s Year: 2007 Pseudomonas, enterobacteriaceae ESBL positive and staphylococcus MRSA: When to suspect them in CAP? Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014 Streptococcus pneumoniae resistance pattern and its clinical implications Source: Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections Year: 2006 The prevalence of antimicrobial resistance of P. aeruginosa, K. pneumoniae, E. coli, A. baumanii in Ukraine Source: International Congress 2014 – Clinical problems in acute and chronic lung diseases Year: 2014 Community-associated methicillin-resistant staphylococcus aureus (CA-MRSA) as a cause of hospital-acquired pneumonia (HAP) Source: Eur Respir J 2007; 30: Suppl. 51, 410s Year: 2007 Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia Source: Eur Respir J 2007; 29: 548-560 Year: 2007 Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia Source: Eur Respir J 2009; 34: 1148-1158 Year: 2009 Methicillin-resistant Staphylococcus aureus (MRSA) active screening in a Pulmonology department. Source: International Congress 2018 – Clinical challenges in respiratory infection Year: 2018 Diagnostic challenge in community-acquired pneumonia and hospital-acquired pneumonia: risk factors and diagnostic methods for methicillin resistant Staphylococcus aureus Source: Annual Congress 2006 - Methicillin resistant Staphylococcus aureus (MRSA): a real hospital-based pathogen? Year: 2006 Mechanisms of acquisition of resistance in Staphylococcus aureus Source: Annual Congress 2006 - Methicillin resistant Staphylococcus aureus (MRSA): a real hospital-based pathogen? Year: 2006 CusS-cusR mediate carbapenem-resistant Klebsiella pneumoniae resistant to tigecycline. Source: International Congress 2019 – Clinical challenges in respiratory infection Year: 2019 Community-acquired pneumonia in Europe: causative pathogens and resistance patterns Source: Eur Respir J 2002; 20: 20S-27S Year: 2002 Treatment challenges in methicillin resistant Staphylococcus aureus infections Source: Annual Congress 2006 - Methicillin resistant Staphylococcus aureus (MRSA): a real hospital-based pathogen? Year: 2006 Macrolide resistance in Pseudomonas aeruginosa: implications for practice Source: Eur Respir J, 49 (5) 1700689; 10.1183/13993003.00689-2017 Year: 2017 Peculiarities of community-acquired pneumonia course, caused by multiresistant strains of S. pneumoniae Source: Eur Respir J 2006; 28: Suppl. 50, 165s Year: 2006